Tag

Your search for Interferon-free treatment returned 29 results.


Exclusive HCV Interview: Julio Gutierrez, MD

So my first question is what do you see as the biggest challenges associated with the hepatitis C epidemic in the U.S.? JULIO GUTIERREZ: There are three main challenges currently associated with eradicating hepatitis C in the United States: Most patients in the US are still not receiving care for their hepatitis C infection. In order to cure HCV in these ...

Read More


Key AASLD 2015 HCV Abstracts: Dr. Lebovics

For more information on the selected AASLD 2015 HCV abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book. Decreased work productivity in patients with chronic hepatitis C Abstract 18 Reduced Work Productivity (WP), Absenteeism and Presenteeism of Patients Infected with ...

Read More


Decentralized HCV Treatment is Effective!

Given the safety, tolerability, simplicity, and efficacy of hepatitis C direct-acting antiviral (DAA) regimens, decentralizing treatment from gastroenterologists and hepatologists to other specialists, community-based primary care physicians, or appropriately supervised mid-level providers (ie, task-shifting) may be an effective strategy to increase treatment rates, ...

Read More


C-SALVAGE: Final 24-week Follow-up Results

Non-cross-resistant drugs are needed for salvage therapy of patients with chronic hepatitis C virus infection who do not achieve sustained virologic response on direct acting antiviral (DAA) regimens. The final follow-up week 24 results from the C-SALVAGE study (Hepatitis C-Salvage Study for Patients who Failed DAA/PR Therapy), have been published in the journal ...

Read More


HCV Drug Costs: A Treatment Access Barrier

In a newly published, thought-provoking article in the journal Clinical Infectious Diseases, Stacey B. Trooskin and colleagues discuss how the high cost of newer hepatitis C therapies has become a major treatment access barrier in the US (Trooskin SB, et al. Clin Infect Dis. 2015 Aug 12 [Epub ahead of print]). Controversial insurance coverage restrictions and ...

Read More


Two DAA regimen in cirrhotic HCV GT1b patients

New Phase 2 clinical trial results indicate that an all-oral interferon- and ribavirin-free regimen of ombitasvir, paritaprevir, and ritonavir is generally well tolerated and associated with high rates of SVR12 in both cirrhotic and noncirrhotic patients with HCV genotype 1b infection who were treatment-naive or treatment experienced, including prior null responders, ...

Read More


GS-5816: a DAA with pan-genotypic HCV activity

The availability of a safe, highly effective, pangenotypic regimen for the treatment of HCV infection would have a major impact on global disease prevalence, as it would be suitable for treatment of all infected persons regardless of genotype. Results of a new phase 1 study demonstrate the safety and potent pan-genotypic HCV activity of GS-5816, a novel inhibitor of ...

Read More


Real-world impact of sofosbuvir HCV regimens

New study addresses the real-world effectiveness of sofosbuvir (SOF)-based anti-HCV regimens in a diverse patient population consisting of difficult to treat patients. More than a quarter of the assessed US Veterans Affairs (VA) population with chronic HCV infection were African American, almost 90% were over the age of 55, over a third were overweight, and substan...

Read More


Addressing the Restricted Use of DAA therapies

Results of a new US cost effectiveness study indicate that effective direct acting antiviral (DAA) therapies should be not be restricted to only those HCV-infected patients with advanced fibrosis. Authors note that as a society, we have an opportunity to eliminate hepatitis C by taking appropriate and timely steps, and we should be willing to pay for the current HCV ...

Read More


HCV DAAs and Severe Renal Impairment

New report provides vital information needed by clinicians to treat HCV in patients with severe renal impairment with the approved DAAs simeprevir and sofosbuvir. Available clinical information on the use of sofosbuvir in patients with severe renal impairment is minimal, and there are currently no approved direct acting antiviral (DAA) treatments in this popula...

Read More